Redefining Biomarkers for Immune-Mediated Disease with AI
Update: 2025-11-13
Description
Ronel Veksler, co-founder and CEO of PromiseBio, sits down with Amar Drawid to discuss the company’s AI-enabled proteomics platform, and how post-translational modifications of proteins represent a new frontier for precision medicine in autoimmune diseases; and how AI is enabling deep profiling of the epiproteome for better disease subtyping, improved prediction of drug response, and more personalized therapeutic strategies.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
